双时相门冬胰岛素30对2型糖尿病患者血糖的影响被引量：2

Influences of biphasic insulin aspart 30 on blood sugar in patients with type 2 diabetes

导出

摘要目的分析2型糖尿病患者口服降糖药控制不满意时加用双时相门冬胰岛素30治疗前后血糖水平的变化,探讨其降糖作用。方法 40例2型糖尿病患者口服降糖药控制不满意时加用双时相门冬胰岛素30治疗24周,观察治疗前后血糖等指标的变化。结果双时相门冬胰岛素30治疗后空腹血糖(FPG)、餐后2 h血糖(PPG)、糖化血红蛋白(HbA1c)、甘油三酯(TG)水平较治疗前显著降低,患者加用双时相门冬胰岛素30治疗后,HbA1c水平<7%及≤6.5%者所占比例较治疗前显著增加。结论双时相门冬胰岛素30可改善口服降糖药控制不满意时2型糖尿病患者的血糖控制及血脂代谢,有助于降低2型糖尿病患者并发症,改善预后。 Objective To analyze the changes of blood glucose before and after the treat- ment of oral hypoglycemic drugs without satisfactory effects and biphasic insulin aspart 30 in pa- tients with type 2 diabetes to investigate its glucose-lowering effect. Methods Forty patients with type 2 diabetes received biphasic insulin aspart 30 for 24 weeks when the effects of oral hypo- glycemic drugs were unsatisfactory. The changes of blood glucose were observed before and after treatment. Results After the treatment of biphasic insulin aspart 30, the levels of fasting plasma glucose （FPG）, postprandial blood glucose （PBG） 2 h after the meal, glycosylated hemoglobin （HbAlc） and triglyceride （TG） decreased more significantly. After patients were administered bio- hasic aspart insulin 30, the proportion of patients with HbAlc level ~ 7% and ^-~6.5 % markedly increased. Conclusion Biphasic insulin aspart 30 can improve glycemic control and lipid metabolism of patients with type 2 diabetes when the effects of oral hypoglycemic drugs are unsatisfactory. It is conductive to decreasing the complications of patients with type 2 diabetes and improving the prog- nosis.

作者陈红芳陈志高丁绍红

机构地区东南大学医学院附属江阴人民医院药物临床试验机构办公室

出处《实用临床医药杂志》 CAS 2013年第1期87-88,97,共3页 Journal of Clinical Medicine in Practice

基金中国高校医学期刊临床专项资金(11220206)

关键词 2型糖尿病双时相门冬胰岛素30 血糖糖化血红蛋白血脂 type 2 diabetes biphasic insulin aspart 30 blood glucose glycosylatedhemoglobin blood lipid

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献10

1Tomesová J,Lacigová S,Cechurová D. Unusual cause of foot defect in patient with diabetes mellitus[J].Vnitrni Lekarstvi,2012,(11):875.
2Symeonidis C,Papakonstantinou E,Galli A. Matrix metalloproteinase (MMP-2,-9) and tissue inhibitor (TIMP-1,-2) activity in tear samples of pediatric type 1 diabetic patients:MMPs in tear samples from type 1 diabetes[J].Greefe's Archive for Clinical and Experimental Ophthalmology,2012.
3Holman R R,Paul S K,Bethel M A. 10-year follow-up of intensive glucose control in type 2 diabetes[J].New England Journal of Medicine,2008,(15):1577.
4Mellbin L G,Malmberg K,Waldenstrm A. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes:a report from the DIGAMI 2 trial[J].Heart,2009,(09):721.
5叶任高;陆再英;王晨.内科学.第5版第5版[M].北京:人民卫生出版社,2004256.
6Yang W,Ji Q,Zhu D. Biphasic insulin aspar 30 three times daily is more effctive than a twice daily regimen,without increasing hypoglycemia,in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs[J].Diabetes Care,2008,(05):852.
7Gao Y,Guo X H,Vaz J A. Biphasic insulin aspar 30 treatment improves glycaemic control inpatients with type 2 diabetes in a clinical practice setting:Chinese PRESENT study[J].Diabetes,Obesity and Metabolism,2009,(01):33.
8Miyashita Y,Nishimurs R,Nemoto M. Prospective randomized study for optimal insulin therspy in type 2 diabetic patients with secondary failure[J].Cardiovascular Diabetology,2008.16.
9Marouf E,Sincair A J. Use of short-acting insulin aspar inmanaging older people with diabetes[J].Clin Interv Aging,2009.187.
10Chisalita S I,Lindatrom T,Eson Jennersjo P. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide at the same glycemic control[J].ACTA DIABETOLOGICA,2009,(01):35.